At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

Another prespecified outcome of the trial, 2-year freedom from all-cause mortality, tricuspid valve surgery, and tricuspid ...

The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

Ben McCullough, 76, received an EVOQUE heart valve last fall. On Wednesday, he got to thank the makers face-to-face.

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

The U.S. Centers for Medicare & Medicaid Services (CMS) issued a draft coverage memo for transcatheter edge-to-edge repair for the tricuspid valve (T-TEER), which is a development that promises ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

The funding will be put towards an early feasibility study, designed to determine the clinical effectiveness and safety of Laplace’s transcatheter tricuspid valve replacement system. If ...

Another prespecified outcome of the trial, 2-year freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention, also greatly favored TEER (77.6% vs 29.3% ...

Get Instant Summarized Text (Gist) Minimally invasive valve repair using a clip significantly reduces heart failure hospitalizations in patients with severe tricuspid regurgitation. At two years ...